Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

On May 17, 2022 Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, reported that Dr. Joseph Tucker, Chief Executive Officer of Enveric, will participate virtually in the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022 (Press release, Enveric Biosciences, MAY 17, 2022, https://www.enveric.com/news/enveric-biosciences-to-participate-in-the-h-c-wainwright-global-investment-conference-on-may-23-26-2022/ [SID1234614749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tucker’s corporate presentation will be available on-demand starting Tuesday, May 24th at 7:00 a.m. ET. Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate H.C. Wainwright representative, or send an email to KCSA Strategic Communications at [email protected].